Bzrap1 Activators
Bzrap1 activators are a group of compounds that are identified and developed to enhance the activity of the Bzrap1 protein. The discovery process for these activators typically begins with high-throughput screening (HTS), a methodological cornerstone in the field of chemical biology. During HTS, large libraries of chemicals are tested for their ability to modulate the activity of Bzrap1. The assays used in HTS are designed to detect changes in Bzrap1 activity, often indicated by alterations in fluorescence, luminescence, or other types of measurable signals that correlate with the protein's function. Compounds that produce a significant increase in the readout are considered hits and selected for further investigation. To confirm the activity of these compounds and to verify that the observed effects are specific to Bzrap1 activation, secondary assays are employed. These assays are more refined and structured to validate the specificity of the interaction between the compounds and Bzrap1. They help to eliminate false positives that may arise from non-specific interactions or indirect effects on the assay rather than a direct engagement with Bzrap1.
Once a subset of compounds has been confirmed as genuine Bzrap1 activators, they are subjected to a series of rigorous characterizations. Structural studies, such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy, are undertaken to ascertain how these activators bind to and interact with the Bzrap1 protein. These studies can reveal the binding site of the activators on the protein and the conformational changes that lead to its activation. This structural information is crucial for understanding the precise mechanism by which the activators increase Bzrap1 activity. In parallel, biophysical approaches, including surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), are used to generate data on the kinetics and affinity of the interaction between the activators and Bzrap1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diester of phorbol and functions as a potent protein kinase C (PKC) activator. By activating PKC, PMA may enhance the phosphorylation status of proteins, including Bzrap1, resulting in increased functional activity if Bzrap1 is a substrate or is regulated by PKC-mediated signaling. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromo-cAMP is a cell-permeable cAMP analog that activates protein kinase A (PKA). If Bzrap1 activity is modulated through PKA-dependent phosphorylation, 8-Bromo-cAMP would lead to the enhancement of Bzrap1 function by increasing its phosphorylation through PKA activation. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionmycin is a calcium ionophore that increases intracellular calcium levels. It can activate calcium-dependent protein kinases and phosphatases, which may enhance the functional activity of Bzrap1 if it is regulated by calcium-dependent signaling mechanisms. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a potent inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels. If Bzrap1 is activated by calcium-dependent pathways, thapsigargin could indirectly increase its activity by elevating intracellular calcium. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Okadaic acid is a potent inhibitor of protein phosphatases PP1 and PP2A. By inhibiting these phosphatases, okadaic acid may lead to increased phosphorylation and activation of Bzrap1 if it is normally dephosphorylated by PP1 or PP2A. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of PKC. Inhibition of PKC can lead to the alteration of downstream signaling pathways and could potentially enhance Bzrap1 activity if Bzrap1 is involved in the pathways that are de-repressed upon PKC inhibition. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol compound from green tea with various biological effects, including kinase inhibition. If Bzrap1 is regulated by kinases that are targets of EGCG, it could lead to the enhancement of Bzrap1 activity through inhibition of negative regulatory kinases. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is another cell-permeable cAMP analog that activates PKA, mimicking the action of cAMP. If Bzrap1 is activated by PKA-dependent phosphorylation, db-cAMP could enhance its activity by increasing PKA signaling. | ||||||